No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission
نویسندگان
چکیده
Jean-Yves Cahn, Myriam Labopin, Jorge Sierra, Didier Blaise, Josy Reiffers, Augustin Ferrant, Lothar Bergmann, Giuseppe Visani, Jan Cornelissen, Theo De Witte, Alberto Bosi, Francesco Frassoni and Norbert-Claude Gorinfor the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Haematology Department, HoÃpital Jean Minjoz, BesancËon, France, EBMT Data Management Office, Paris, France, Hospital Clinic, IDIBAPS, Barcelona, Spain, Institut Paoli-Calmettes, Marseille, France, HoÃpital du Haut-LeveÃque, Pessac, France, Clinique Universitaire Saint-Luc, Bruxelles, Belgium, University Hospital Robert Koch, Ulm, Germany, Hospital San Orsola, Bologna, Italy, Dr Daniel Den Hoed Cancer Centre, Rotterdam, The Netherlands, University Hospital St Radboud, The Netherlands, Ospedale di Careggi, Firenze, Italy, Ospedale San Martino, Genova, Italy, and HoÃpital Saint-Antoine, Paris, France
منابع مشابه
Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.
OBJECTIVE To measure the effects of changes in treatment of acute myeloblastic leukaemia that may give better value for money. DESIGN Retrospective analysis of patients' notes to identify items of management costing money; prospective costing of these items. The Medical Research Council acute myeloblastic leukaemia 9 trial was used to identify the amount and distribution of these costs when e...
متن کاملFacial psoriasis with cytarabine/daunorubicin: A case report
Psoriasis is a common chronic inflammatory skin disease. The most common form of psoriasis is characterized by sharply demarcated, scaly, erythematous plaques. The face is an unusual site for psoriasis. Herein, we report a 43-year-old woman with facial psoriasis that was developed after remission–induction chemotherapy for acute leukemia with high dose cytarabine/daunorubicin.
متن کامل[Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside].
We report the outcome of 95 patients older than 60 years with de novo acute non-lymphocytic leukaemia (ANLL), treated in two institutions during a 10 year period. Thirty-two patients, mean age 78 years, did not receive any chemotherapy, and their median survival was 38 days. Five patients in good clinical condition, aged 60-63 years, were treated conventionally with an anthracycline and cytarab...
متن کاملDouble induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
PURPOSE Intensification by high-dose cytarabine in postremission or induction therapy and prolonged maintenance are established strategies to improve the outcome in patients with acute myeloid leukemia (AML). Whether additional intensification can add to this effect has not yet been determined. PATIENTS AND METHODS A total of 1,770 patients (age 16 to 85 years) with de novo or secondary AML o...
متن کاملAcute Myeloblastic Leukaemia
Myeloblastic leukaemia (A.M.L.) and its closely related cytological variants are less responsive to chemotherapy than acute lymphoblastic leukaemia (A.L.L.). A considerable problem still exists with remission induction; a high proportion of patients fail to achieve complete remission, especially among older adults with the disease. The contribution of maintenance chemotherapy after remission is...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2000